HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) has announced pre-clinical data for HMPL-A830, its first-in-class Antibody-Targeted Therapy Conjugate (ATTC), presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Barcelona on 18–20 November 2026. The drug candidate combines a pan-KRAS small molecule inhibitor payload with an anti-EGFR antibody, targeting cancers where KRAS mutations drive aggressive disease progression. The disclosure follows an exclusive development and licence agreement signed with a GSK subsidiary in September 2026, with a global Phase I trial already under way.

Key Points

  • HUTCHMED (China) Limited (HCM) — listed on Nasdaq/AIM and HKEX
  • Pre-clinical data for HMPL-A830 presented at the 38th EORTC-NCI-AACR conference in Barcelona, November 2026
  • HMPL-A830 showed potent antiproliferative activity across 55 tumour cell lines harbouring diverse KRAS mutations including G12C, G12D, G12V and G13D
  • Investors should watch progress of the ongoing global Phase I trial (NCT07718581) evaluating HMPL-A830 in patients with advanced solid tumours

HMPL-A830's Dual-Action Mechanism Targets Both KRAS ON and OFF States Across Multiple Mutations

In vitro profiling detailed in the announcement shows that HMPL-A830's pan-KRAS payload simultaneously blocks KRAS "ON" state GTP-RAF1 binding and "OFF" state GDP-to-GTP exchange. The candidate demonstrated potent antiproliferative activity across 55 tumour cell lines carrying a broad range of KRAS alterations, including G12C, G12D, G12V, and G13D mutations as well as wild-type amplification. The announcement states it also exhibited high binding affinity, rapid internalisation into EGFR-positive cells, strong bystander killing of neighbouring EGFR-negative tumour cells, and robust antibody-dependent cellular cytotoxicity activity — a combination of properties HUTCHMED positions as addressing unmet need in KRAS-driven oncology.

Mouse Model Results Show HMPL-A830 Outperforming KRAS G12C Inhibitors and Comparative Regimens

In mouse models, HMPL-A830 demonstrated dose-dependent antitumour efficacy across multiple EGFR-positive tumour models. The announcement states the candidate achieved more durable tumour regressions than KRAS G12C inhibitors and outperformed several comparative regimens, including its unconjugated antibody, a pan-RAS inhibitor administered alone or combined with cetuximab, and a TROP2-targeted antibody-drug conjugate. Pharmacokinetic and pharmacodynamic analyses confirmed stronger and more sustained inhibition of EGFR and KRAS downstream signalling than the naked antibody, with a stable drug-to-antibody ratio maintained across mouse, monkey, and human plasma samples.

GSK Licence Agreement and Global Phase I Trial Define HMPL-A830's Near-Term Development Path

In September 2026, HUTCHMED Limited — a subsidiary of the company — entered into an exclusive development and licence agreement with a GSK subsidiary, granting worldwide rights excluding Mainland China, Hong Kong, Macau, and Taiwan to develop and commercialise HMPL-A830. HUTCHMED retains responsibility for the global Phase I development programme, while the GSK subsidiary will lead all subsequent clinical development and commercialisation activities outside those territories. The Phase Ia portion of the global Phase I trial is currently evaluating HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumours under trial identifier NCT07718581.

KRAS Mutation Prevalence Across CRC, NSCLC and Pancreatic Cancer Underpins HUTCHMED's ATTC Strategy

The announcement contextualises HMPL-A830 within a substantial addressable clinical need, noting that KRAS is mutated in approximately 44% of colorectal cancer patients, 34% of lung adenocarcinoma patients, and up to 89% of pancreatic ductal adenocarcinoma patients. HUTCHMED's broader ATTC platform, built on over 20 years of targeted therapy expertise, is designed to combine monoclonal antibodies with proprietary small-molecule payloads to deliver synergistic anti-tumour activity. Key risks include the inherent uncertainties of translating pre-clinical results into clinical efficacy, regulatory approval timelines, and HUTCHMED's reliance on partnership execution with GSK for commercialisation outside its core Asian territories.